[New diagnostic and therapeutic possibilities in neonatal sepsis].
Neonatal sepsis remains a major clinical problem in neonatology, with high morbidity and mortality rates. The host defence against infections is immature in the newborn infant, and this makes the child more susceptible to invasive infection. The neutrophil storage pool and various granulocyte functions are impaired. In addition, the levels of immunoglobulins and complement are low. The detection of raised levels of complement activation products and cytokines may be of diagnostic help at an early stage of neonatal infection. Rapid treatment with antibiotics is essential for a favourable outcome. Possible adjuvant treatment may be to reduce the relative immunodeficiency by giving immunoglobulins or colony-stimulating factors which increase the production of leukocytes. Further, the potent inflammatory reaction initiated by the microorganisms may be suppressed by various therapies. In spite of much research in this field, no such adjuvant treatment has so far been shown to improve the outcome of neonatal sepsis.
Høgåsen
A K
AK
Barneklinikken Rikshospitalet, Oslo.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D018805:Sepsis / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D012772:Shock, Septic / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents